TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study VEG108844, A Study of Pazopanib Versus Sunitinib in the Treatment of Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Brief Summary: This was a randomized, open-label, parallel group Phase III non inferiority study to evaluate the efficacy and safety of pazopanib compared with sunitinib in subjects with advanced renal cell carcinoma (RCC) who had not received prior systemic therapy for advanced or metastatic RCC.


Options:
A: Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib, Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Control Arm; Type: ACTIVE_COMPARATOR; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Drug: Cabozantinib-matched placebo | Intervention Type: DRUG; Name: Cabozantinib; Assigned to Arm(s): Experimental Arm | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Control Arm, Experimental Arm | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Control Arm, Experimental Arm | Intervention Type: DRUG; Name: Cabozantinib-matched placebo; Assigned to Arm(s): Control Arm
B: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib, Drug: AMG 386 placebo IV | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib | Arm Label: Arm C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib, Drug: AMG 386 placebo IV | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: AMG 386 placebo IV; Assigned to Arm(s): Arm A, Arm C
C: Arm Label: Atezolizumab and Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab | Arm Label: Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab, Drug: Sunitinib | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody; Assigned to Arm(s): Atezolizumab, Atezolizumab and Bevacizumab, Sunitinib | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Atezolizumab, Atezolizumab and Bevacizumab, Sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
D: Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Exercise Intervention for Breast Cancer Patients: Feasibility and Effectiveness (BEAT Cancer Trial)
Brief Summary: "Translation" of the current "basic science" information related to physical activity into patient intervention programs is needed. This translation is critical to providing benefit to the maximum number of patients. Little is known about the determinants of physical activity among breast cancer patients undergoing hormonal therapy and few studies have attempted to evaluate an exercise behavior change program aimed to improve exercise adherence among such patients. The proposed project will evaluate use of an innovative behavioral and psychosocial intervention to increase physical activity among breast cancer patients.


Options:
A: Arm Label: Resistance training; Type: ACTIVE_COMPARATOR; Interventions: Other: Supervised progressive resistance training | Arm Label: Relaxation training; Type: ACTIVE_COMPARATOR; Interventions: Other: Supervised progressive muscle relaxation training (Jacobson method) | Intervention Type: OTHER; Name: Supervised progressive resistance training; Assigned to Arm(s): Resistance training | Intervention Type: OTHER; Name: Supervised progressive muscle relaxation training (Jacobson method); Assigned to Arm(s): Relaxation training
B: Arm Label: Swallowing therapy & resistance training; Type: EXPERIMENTAL; Interventions: Behavioral: Swallowing therapy & resistance training | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Swallowing therapy & resistance training; Assigned to Arm(s): Swallowing therapy & resistance training
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: exercise | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: exercise; Assigned to Arm(s): A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Behavior Change | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise Behavior Change; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Internet Health Research Center: Smoking, Latinos, and the Web
Brief Summary: The purpose of this study is to determine the percentage of English- and Spanish-speaking smokers worldwide who can stop smoking using an Internet stop smoking site.

Latinos and non-Latinos are welcome to participate.

We will stop recruitment on March 19, 2011. Participants will be able to use the site until May 19, 2011.


Options:
A: Arm Label: Telephone counselling; Type: EXPERIMENTAL; Interventions: Device: Standard 15-minute telephone counselling, Device: Proactive telephone counselling | Arm Label: Proactive telephone counselling; Type: EXPERIMENTAL; Interventions: Device: Proactive telephone counselling | Arm Label: web-based smoking cessation programme; Type: EXPERIMENTAL; Interventions: Device: Interactive web-based smoking cessation programme | Arm Label: Self-help material; Type: ACTIVE_COMPARATOR; Interventions: Device: Self-help material | Intervention Type: DEVICE; Name: Standard 15-minute telephone counselling; Assigned to Arm(s): Telephone counselling | Intervention Type: DEVICE; Name: Proactive telephone counselling; Assigned to Arm(s): Proactive telephone counselling, Telephone counselling | Intervention Type: DEVICE; Name: Interactive web-based smoking cessation programme; Assigned to Arm(s): web-based smoking cessation programme | Intervention Type: DEVICE; Name: Self-help material; Assigned to Arm(s): Self-help material
B: Arm Label: Information Prescription; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking Coach | Arm Label: QUIT-PRIMO; Type: EXPERIMENTAL; Interventions: Behavioral: Decide2Quit | Intervention Type: BEHAVIORAL; Name: Decide2Quit; Assigned to Arm(s): QUIT-PRIMO | Intervention Type: BEHAVIORAL; Name: Smoking Coach; Assigned to Arm(s): Information Prescription
C: Arm Label: Electronic Referrals; Type: EXPERIMENTAL; Interventions: Other: Electronic Referral | Arm Label: Routine Referral; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Electronic Referral; Assigned to Arm(s): Electronic Referrals
D: Arm Label: San Francisco Internet Stop Smoking Site; Type: EXPERIMENTAL; Interventions: Behavioral: UCSF/SFGH Internet Stop Smoking Study site | Intervention Type: BEHAVIORAL; Name: UCSF/SFGH Internet Stop Smoking Study site; Assigned to Arm(s): San Francisco Internet Stop Smoking Site

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence
Brief Summary: Cigarette smoking is of great public health importance and is the single most important preventable cause of morbidity, mortality and excess health care costs in the United States. After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 21%. Currently available treatments among adults are not efficacious for all tobacco users. New pharmacologic agents thus need to be continually developed and tested.

The release of dopamine in the nucleus accumbens is one of the key components of the pleasurable and rewarding effects of nicotine. Drugs that increase monoamine neurotransmitter availability (particularly dopamine and norepinephrine) are likely to increase the reward function and thus ameliorate withdrawal symptoms. S-Adenosyl-L-Methionine (SAMe), the primary methyl donor for the central nervous system (CNS), donates methyl groups towards presynaptic synthesis of CNS monoamine neurotransmitters. By facilitating the synthesis of dopamine and norepinephrine in the brain, SAMe is likely to ameliorate the symptoms of nicotine withdrawal, thus improving tobacco abstinence rates in smokers who are trying to stop smoking. SAMe is well tolerated and is available over-the-counter.

To date, no prospective clinical trial evaluating the efficacy of SAMe for the treatment of tobacco dependence has been published. We propose to evaluate the efficacy of SAMe for increasing smoking abstinence and decreasing nicotine withdrawal symptoms in a randomized, blinded, placebo-controlled, three-arm, parallel-group, dose-ranging phase II clinical trial. Participants (N=120) will be randomly assigned to one of the three groups, and will receive an 8-week course of SAMe 800-mg per day, 1600-mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism, if the results appear promising.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: SSR591813L (dianicline); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: bupropion SR (sustained-release); Assigned to Arm(s): N/A
D: Arm Label: SAMe 800; Type: ACTIVE_COMPARATOR; Interventions: Drug: S-Adenosyl-L-Methionine | Arm Label: SAMe 1600; Type: ACTIVE_COMPARATOR; Interventions: Drug: S-Adenosyl-L-Methionine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: S-Adenosyl-L-Methionine; Assigned to Arm(s): SAMe 800 | Intervention Type: DRUG; Name: S-Adenosyl-L-Methionine; Assigned to Arm(s): SAMe 1600 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient Perception of Symptom Variability. A Cross-sectional Study of Patients With Severe COPD.
Brief Summary: This study is investigating how patients with severe stable state COPD perceive the variability of their symptoms throughout the day, the week and the year; the impact of these variations on their daily activities or sleep quality and how they deal with their treatments. For this purpose patients will be asked to answer a questionnaire over the phone


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Training with e-health product | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Training with e-health product; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Control
B: Arm Label: Group A, Telerehabilitation; Type: EXPERIMENTAL; Interventions: Other: Telerehabilitation | Arm Label: Group B, Hospital based Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Other: Hospital based Rehabilitation | Arm Label: Group C, Usual care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Telerehabilitation; Assigned to Arm(s): Group A, Telerehabilitation | Intervention Type: OTHER; Name: Hospital based Rehabilitation; Assigned to Arm(s): Group B, Hospital based Rehabilitation
C: N/A
D: Arm Label: Tool + Self-management Support Program; Type: EXPERIMENTAL; Interventions: Device: Tool, Behavioral: Self-management Support Program | Arm Label: Self- management Support Program; Type: EXPERIMENTAL; Interventions: Behavioral: Self-management Support Program | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Tool; Assigned to Arm(s): Tool + Self-management Support Program | Intervention Type: BEHAVIORAL; Name: Self-management Support Program; Assigned to Arm(s): Self- management Support Program, Tool + Self-management Support Program

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Double-blind Trial of Intravenous Immunoglobulin for Women With Unexplained Secondary Recurrent Miscarriage
Brief Summary: The investigators want to test whether infusions of intravenous immunoglobulin - a blood product known to modify immune responses - in early pregnancy will increase the chance of a subsequent live birth in women with three or more miscarriages after a birth and a total of at least four miscarriages. This will be done in a trial where 82 patients will be randomly allocated to infusions with intravenous immunoglobulin or placebo during pregnancy.


Options:
A: Arm Label: IvIg; Type: EXPERIMENTAL; Interventions: Drug: Intravenous immunoglobulin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Human albumin | Intervention Type: DRUG; Name: Intravenous immunoglobulin; Assigned to Arm(s): IvIg | Intervention Type: DRUG; Name: Human albumin; Assigned to Arm(s): placebo
B: Arm Label: Low molecular weight heparin; Type: N/A; Interventions: Drug: low molecular weight heparin (enoxeparine) | Intervention Type: DRUG; Name: low molecular weight heparin (enoxeparine); Assigned to Arm(s): Low molecular weight heparin
C: Arm Label: Standard of Care Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low-molecular-weight heparin | Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Drug: Aspirin 81 mg | Intervention Type: DRUG; Name: Aspirin 81 mg; Assigned to Arm(s): Experimental Arm | Intervention Type: DRUG; Name: Low-molecular-weight heparin; Assigned to Arm(s): Standard of Care Arm
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gamimune N or Gamunex 10% | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: normal saline | Intervention Type: BIOLOGICAL; Name: Gamimune N or Gamunex 10%; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: normal saline; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label Randomized Study of Subcutaneous and Intravenous VELCADE in Subjects With Previously Treated Multiple Myeloma
Brief Summary: Randomized, open-label, international, multi-center, Phase 3 study in which patients are randomized to receive VELCADE administered by subcutaneous injection or intravenous infusion.


Options:
A: Arm Label: Velcade-Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Velcade-Dexamethasone | Arm Label: Velcade-Thalidomide-Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Velcade-Thalidomide-Dexamethasone | Intervention Type: DRUG; Name: Velcade-Dexamethasone; Assigned to Arm(s): Velcade-Dexamethasone | Intervention Type: DRUG; Name: Velcade-Thalidomide-Dexamethasone; Assigned to Arm(s): Velcade-Thalidomide-Dexamethasone
B: Intervention Type: DRUG; Name: bortezomib; Assigned to Arm(s): N/A
C: Arm Label: VDR; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: Revlimid (lenalidomide) | Arm Label: VDCR; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide, Drug: Revlimid (lenalidomide) | Arm Label: VDC; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide | Arm Label: VDC-mod; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide | Intervention Type: DRUG; Name: VELCADE (bortezomib); Assigned to Arm(s): VDC, VDC-mod, VDCR, VDR | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): VDC, VDC-mod, VDCR, VDR | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): VDC, VDC-mod, VDCR | Intervention Type: DRUG; Name: Revlimid (lenalidomide); Assigned to Arm(s): VDCR, VDR
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: VELCADE Administered by subcutaneous injection | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: VELCADE Administered by intravenous infusion | Intervention Type: DRUG; Name: VELCADE Administered by subcutaneous injection; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: VELCADE Administered by intravenous infusion; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil/Caelyx) in Combination, Versus PLD Alone, in Subjects With Platinum-Resistant Ovarian Cancer
Brief Summary: The objective of this study is to compare progression-free survival (PFS), based upon investigator assessment using Response Evaluation Criteria In Solid Tumors version 1.0 (RECIST 1.0) and clinical findings, in participants with platinum-resistant ovarian cancer who receive combination therapy with vintafolide and pegylated liposomal doxorubicin (PLD/Doxil®/Caelyx®) with that in subjects with platinum-resistant ovarian cancer who receive PLD alone.


Options:
A: Arm Label: Sorafenib (Nexavar, BAY43-9006); Type: EXPERIMENTAL; Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sorafenib (Nexavar, BAY43-9006); Assigned to Arm(s): Sorafenib (Nexavar, BAY43-9006) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: DOXIL + trabectedin; Type: EXPERIMENTAL; Interventions: Drug: Trabectedin, Drug: DOXIL, Drug: Dexamethasone | Arm Label: DOXIL; Type: ACTIVE_COMPARATOR; Interventions: Drug: DOXIL | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): DOXIL + trabectedin | Intervention Type: DRUG; Name: DOXIL; Assigned to Arm(s): DOXIL, DOXIL + trabectedin | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): DOXIL + trabectedin
C: Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): N/A
D: Arm Label: Vintafolide + PLD; Type: EXPERIMENTAL; Interventions: Drug: Vintafolide, Drug: pegylated liposomal doxorubicin (PLD), Other: EC20 | Arm Label: PLD Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pegylated liposomal doxorubicin (PLD), Other: EC20 | Intervention Type: DRUG; Name: Vintafolide; Assigned to Arm(s): Vintafolide + PLD | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): PLD Alone, Vintafolide + PLD | Intervention Type: OTHER; Name: EC20; Assigned to Arm(s): PLD Alone, Vintafolide + PLD

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil/Caelyx) in Combination, Versus PLD Alone, in Subjects With Platinum-Resistant Ovarian Cancer
Brief Summary: The objective of this study is to compare progression-free survival (PFS), based upon investigator assessment using Response Evaluation Criteria In Solid Tumors version 1.0 (RECIST 1.0) and clinical findings, in participants with platinum-resistant ovarian cancer who receive combination therapy with vintafolide and pegylated liposomal doxorubicin (PLD/Doxil®/Caelyx®) with that in subjects with platinum-resistant ovarian cancer who receive PLD alone.


Options:
A: Arm Label: Patupilone; Type: EXPERIMENTAL; Interventions: Drug: EPO906 (Patupilone) | Arm Label: doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: doxorubicin | Intervention Type: DRUG; Name: EPO906 (Patupilone); Assigned to Arm(s): Patupilone | Intervention Type: DRUG; Name: doxorubicin; Assigned to Arm(s): doxorubicin
B: Intervention Type: DRUG; Name: TLK286; Assigned to Arm(s): N/A
C: Arm Label: Vintafolide + PLD; Type: EXPERIMENTAL; Interventions: Drug: Vintafolide, Drug: pegylated liposomal doxorubicin (PLD), Other: EC20 | Arm Label: PLD Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pegylated liposomal doxorubicin (PLD), Other: EC20 | Intervention Type: DRUG; Name: Vintafolide; Assigned to Arm(s): Vintafolide + PLD | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): PLD Alone, Vintafolide + PLD | Intervention Type: OTHER; Name: EC20; Assigned to Arm(s): PLD Alone, Vintafolide + PLD
D: Arm Label: Telcyta + Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Drug: Telcyta, Drug: Liposomal Doxorubicin | Arm Label: Liposomal Doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Intervention Type: DRUG; Name: Telcyta; Assigned to Arm(s): Telcyta + Liposomal Doxorubicin | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin, Telcyta + Liposomal Doxorubicin

Answer: C